Shares of Coherus BioSciences CHRS were flat in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 97.92% year over year to $0.01, which missed the estimate of $0.06.
Revenue of $83,034,000 declined by 28.53% from the same period last year, which missed the estimate of $96,000,000.
Looking Ahead
Coherus BioSciences hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 06, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/rzowgi5s
Technicals
Company's 52-week high was at $22.22
52-week low: $13.53
Price action over last quarter: down 4.92%
Company Description
Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
